Bailey Pemberton
4 min read
OPKO Health has climbed in 2024 yet carries a much longer track record that includes a steep multi year decline, which puts a spotlight on whether the current share price lines up with the revenue story. With the stock trading at US$1.72, the key question is how that tag compares with what the business actually generates in sales.
-
OPKO Health shareholders have seen the stock fall 58.4% over the past 5 years, so any reassessment of its worth now hinges heavily on what its revenue base can plausibly support.
-
The first patient dosing in the Phase 1/2a trial of OPK-8801001 for acromegaly may support expectations for future product driven sales, along with the funding and timing assumptions that go into valuing those potential revenues.
-
Your read on OPKO Health is one view; the desks covering it have another. See what analysts think OPKO Health’s shares could be worth.
The issue now is whether OPKO Health’s recent share price, after that long term drawdown and newer clinical progress, can be justified by its sales.
If you are weighing OPKO Health against other ideas that also anchor valuation on sales, a focused screen of 34 high quality undervalued stocks can be a useful second starting point for your research.
Does OPKO Health Look Pricey on Sales?
P/S is a useful lens for OPKO Health because the business is still shaped by losses and early pipeline work, so earnings based metrics do not tell much. On this measure, the stock trades at a P/S of 2.2x, compared with about 1.4x for the broader Healthcare group and 1.6x across closer peers. This points to a richer tag per dollar of current revenue.
The valuation model that blends OPKO Health’s size, margins, risk profile and sector into a tailored fair multiple suggests the current P/S is above what those economics would usually support. The gap is large enough that it reads more as a warning flag than a precise target. Despite the first dosing in the OPK-8801001 acromegaly trial lifting interest in the story, the present P/S still asks you to pay a premium versus both the sector and peer group while the market waits to see how that pipeline converts into future sales. Explore the numbers behind OPKO Health’s P/S valuation.
The OPKO Health Narrative: What Would Justify Today’s Price?
Narratives for OPKO Health pick up where the P/S puzzle leaves off and describe what kind of developments in growth, profitability and earnings would need to occur for the current share price to appear meaningfully higher or lower. Each scenario links a fair value estimate to a clear view of OPKO Health’s potential catalysts and drawbacks, allowing you to track over time which storyline appears closest to reality on Simply Wall St’s Community page.
